After intersecting the targets of GA with those of ovarian cancer and removing duplicates, 115 common targets were obtained (Figure 2A). A PPI network was constructed, and the top 15 core targets for ovarian cancer treatment were identified as ALB, ESR1, EGFR, SRC, BCL2, SMAD3, PTGS2, PARP1, CDK2, SERPINE1, CYP19A1, CXCL12, KDR, IGF1R, and ESR2 (Figure 2B). Molecular docking results showed that GA had strong binding affinity to the core targets of ovarian cancer, with CXCL12 and PARP1 having binding energies less than -6.0 Kcal/mol (28) in three different molecular docking tools, indicating good docking effects (Table 2).This suggests that the synergistic mechanism of gallic acid and cisplatin (DDP) may be related to the targeting of key proteins such as CXCL12 and PARP1.

Transcriptome sequencing results were analyzed for trends and differential gene expression using the DESeq2 algorithm, identifying 63 commonly upregulated genes and 308 commonly downregulated genes. GO enrichment analysis revealed that biological processes (BP) in ID8 ovarian cancer cells were mainly enriched in phosphatidylinositol 3-kinase signaling, transforming growth factor-β receptor signaling, apoptosis, and cell proliferation (P<0.05); cellular components (CC) were primarily enriched in the extracellular matrix, basement membrane, and plasma membrane regions (P<0.05); and molecular functions (MF) were mainly enriched in protein binding, signal receptor binding, and signal receptor activation (P<0.05) (Figure 2C). KEGG enrichment analysis was primarily focused on the PI3K-Akt signaling pathway, TGF-beta signaling pathway, ECM-receptor interaction, axon guidance, and Rap1 signaling pathway (Figure 2D).Transcriptome analysis suggests that GA treatment may inhibit the proliferation and promote apoptosis of ID8 ovarian cancer cells by significantly affecting key signaling pathways such as PI3K-Akt and TGF-β.

Hoechst 33258 staining results (Figure 3A) showed that compared with the control group, the blue fluorescence intensity of A2780 and ES - 2 cells increased with the concentration of GA, indicating an increase in apoptotic cells and a decrease in cell numbers. This demonstrates that GA can effectively induce apoptosis in ovarian cancer A2780 and ES - 2 cells.

Flow cytometry results (Figures 3B, C) showed that compared with the untreated group, the apoptosis rates of A2780 and ES - 2 cells treated with GA (20, 40, 60 µM) for 48 hours significantly increased (all P<0.01) and rose with increasing drug concentration. For ID8 cells, the apoptosis rate was low when treated with GA or cisplatin alone, but when treated with the same concentration in combination, the apoptosis rate significantly increased and rose with increasing drug concentration, with rates of 47.02% and 67.42%, respectively. This indicates that the combination of GA and cisplatin can produce a significant synergistic effect in inducing apoptosis in ovarian cancer cells.

Further Western blot analysis of apoptosis-related proteins revealed that compared with the untreated group, after 48 hours of GA treatment, the expression levels of PARP and Cleaved PARP proteins increased in A2780 and ES - 2 cells (P<0.05) (Figures 4A, B). In A2780 cells, the expression of PI3K p110α, AKT, P-AKT, mTOR, and P-mTOR was inhibited, and this trend became more pronounced with increasing GA concentration. In ES - 2 cells, the expression of PI3K/AKT/mTOR pathway-related proteins was not inhibited. In ovarian cancer ID8 cells, compared with the control, GA-only, and DDP-only groups, the expression of CXCL12 and CXCR4 was significantly inhibited in the combination treatment group, and the expression of downstream PI3K, AKT, P-AKT, and mTOR was also inhibited, with this trend becoming more pronounced with increasing GA concentration. The expression of phosphorylated mTOR did not change significantly. Additionally, the expression of TGF-β1 and β-catenin proteins was also significantly reduced in the combined GA and DDP treatment (Figure 4C). In summary, this study confirmed that gallic acid can effectively induce apoptosis of ovarian cancer cells and synergize with cisplatin. Its molecular mechanism is cell-type-specific and is achieved in A2780 and ID8 cells by inhibiting CXCL12/CXCR4 and PI3K/AKT/mTOR pathway signaling, while in ES - 2 cells it functions in other ways that do not rely on this pathway.

Immunohistochemical staining was used to detect the expression of Ki67 and Cleaved-PARP in the xenograft tumor tissues of C57BL/6J mice with ovarian cancer. Positive staining for Ki67 and Cleaved-PARP was located in the nuclei. The staining results (Figures 7B, C) showed that after GA treatment, the expression of Ki67 in the xenograft tumor tissues of ID8 cells decreased, and the expression of Ki67 in the combination treatment group of GA and DDP was significantly lower than that in the single GA and single DDP groups, with statistically significant differences (P<0.001). Compared with the control group, the expression of Cleaved-PARP in the xenograft tumor tissues of ID8 cells increased in the treated group (Figure 7D), indicating that GA can effectively inhibit ovarian cancer proliferation in vivo, and its combination with DDP can produce a synergistic effect.

Ovarian cancer remains the most lethal gynecological malignancy largely because of rapid acquisition of platinum resistance. Active monomers and secondary metabolites extracted from natural plants are important sources for the development of new drugs and have unique advantages in the treatment of malignant tumors (29). While gallic acid (GA) has repeatedly been reported to inhibit ovarian cancer cell proliferation (9–11), the majority of these studies were confined to in vitro cytotoxicity or single-pathway descriptions. The present work provides the first integrated demonstration that GA markedly sensitizes platinum-resistant ovarian cancer to cisplatin by rewiring the CXCL12/CXCR4-PI3K/AKT/mTOR axis and translates this mechanism into prolonged survival in an immune-competent orthotopic model.

The PI3K/AKT/mTOR signaling pathway is a key intracellular signaling pathway closely related to tumor cell proliferation, apoptosis, angiogenesis, metastasis, and resistance to radiotherapy and chemotherapy. Dong et al. (30) found that upregulation of the PI3K/AKT pathway is a potential indicator of lack of response to neoadjuvant chemotherapy in stage II/III breast cancer patients. Jin et al. (31) identified through whole-exome sequencing and mass spectrometry-based proteomics that PI3K/AKT signaling pathway-related genes are upregulated in small cell lung cancer tissues, suggesting that PI3K/AKT pathway activation may be a potential mechanism of chemoradiotherapy resistance in small cell lung cancer.

Active monomers from medicinal plants can significantly enhance the anticancer effects of chemotherapeutic drugs by inhibiting the PI3K/AKT/mTOR pathway. Di et al. (32) demonstrated that Ailanthone increases cisplatin-induced apoptosis and autophagy in non-small cell lung cancer cells via PI3K/AKT/mTOR. Curcumin can inhibit the PI3K/AKT and JAK/STAT3 pathways in ovarian cancer cells to enhance the anticancer effects of cisplatin (33). Jiang et al. (34) found that Fisetin enhanced cisplatin sensitivity in renal cell carcinoma through the CDK6/PI3K/Akt/mTOR signaling pathway. Fucoidan Enhances Cisplatin-induced Effects on SCC - 25 Human Oral Cancer Cells by Inhibiting the PI3K/AKT Pathway (35). GSK3 (glycogen synthase kinase 3) is a highly conserved serine/threonine kinase that plays an important role in the degradation of cytoskeletal protein β-catenin and apoptosis (36). After AKT phosphorylates GSK3, GSK3 is inactivated, leading to the accumulation of β-catenin in the cytoplasm and its translocation into the nucleus, activating genes related to cell division and growth regulation. Concurrently, AKT activation accelerates glycolysis, increases ATP production, and inhibits apoptosis (37). Therefore, GA inhibits AKT, thereby reversing the inactivation of GSK3 and promoting β-catenin degradation, thereby enhancing the apoptotic effects of cisplatin on ovarian cancer cells.

CXCL12 (CXC chemokine ligand 12) belongs to the CXC chemokine family and plays multiple roles in cell homing and tumor metastasis (38). CXCR4 (CXC chemokine receptor 4) is the specific receptor for CXCL12. The binding of CXCL12 and CXCR4 is specific and one-to-one, hence the term CXCL12/CXCR4 axis. This axis is involved in various pathological and physiological processes, including intercellular communication, immune response mediation, angiogenesis, and tumor invasion and metastasis (39, 40). Yin et al. (41) found that CXCL12 can activate the serine/threonine kinase AKT through autocrine or paracrine signaling, leading to the degradation of collagen fibers, disruption of the basement membrane, and induction of tumor cell proliferation, migration, and invasion. Clearly, the PI3K/AKT/mTOR signaling pathway is one of the downstream pathways of the CXCL12/CXCR4 axis and plays an important role in tumor metastasis and angiogenesis. Activated PI3K generates PIP3, which promotes AKT phosphorylation and translocation to the nucleus, releases the inhibitory effect of mTOR on the inhibitory protein, activates TORC1, promotes mTOR phosphorylation, and thereby mediates cell proliferation and exerts oncogenic functions (42).

AKT hyper-phosphorylation is now recognized as a core driver of platinum efflux, enhanced DNA-damage repair and anti-apoptotic signaling in ovarian cancer (43). Yet direct PI3K or AKT inhibitors have been limited by on-target metabolic toxicities. We discovered that GA does not directly bind PI3K catalytic subunits (Table 1); instead, it down-regulates CXCL12 transcription, thereby disrupting the CXCL12/CXCR4 autocrine loop that normally maintains PI3K membrane recruitment and AKT Ser473 phosphorylation. This mode of action is consistent with findings in these breast cancers where CXCR4 blockade restored sensitivity to PI3K inhibitors (44, 45), but has never been studied in ovarian cancer and has never been associated with GA.

Earlier reports showed GA could inhibit proliferation via ROS/ERK (11) or PTEN/AKT/HIF-1α (10); however, none examined cisplatin synergy or survival extension. Here, CompuSyn analysis revealed strong synergy (CI < 0.7) at clinically achievable GA concentrations (75 – 150 μM), and—critically—median survival increased from 30 to 51 days in the ID8 peritoneal model (Figure 6). This is the first in vivo evidence that GA converts a platinum-refractory phenotype into a platinum-responsive state.

Multi-omics integration highlights GA as an epigenetic-immune-metabolic modulator. Through network pharmacology, molecular docking and transcriptome sequencing, transcriptome analysis identified 308 down-regulated genes enriched in PI3K-Akt and TGF-β pathways. Pathway interaction analysis (Cytoscape 3.9.1) identified CXCL12 as a major regulator and its inhibition inhibited both MTOR-driven glycolysis (HK2, LDHA downregulation) and TGF-β-mediated EMT (SNAI1, VIM inhibition). This pleiotropy is consistent with the 2024 single-cell Atlas of high-grade serous ovarian Cancer, which identified CXCL12 high tumor cells as a platinum-resistant glycolytic subset (46). The key pathways of GA in the treatment of ovarian cancer may be CXCL12/CXCR4 axis and PI3K/AKT/mTOR signaling pathway. Based on the in vitro experiments, the anti-ovarian cancer cell mechanism of GA was explored, and it was confirmed that GA may inhibit cell proliferation and induce cell apoptosis by regulating the PI3K/AKT/mTOR related pathway. The combination of GA and DDP also achieved good combined anti-tumor effect. The combination of GA and DDP promoted the apoptosis of ovarian cancer cells induced by DDP, and also jointly regulated the CXCL12/CXCR4 axis and PI3K/AKT/mTOR related pathways. In addition, it may regulate TGF-β1 and β-catenin related proteins to exert anti-ovarian cancer activity. It is worth noting that GA did not effectively reduce the expression level of p-mTOR in this study, suggesting that there is a compensatory mechanism within the PI3K/Akt/mTOR pathway to maintain its phosphorylation state (47). When Akt is strongly inhibited, negative feedback inhibition of upstream signals (such as receptor tyrosine kinase RTKs) or parallel pathways (such as MAPK pathways) may be undone, resulting in compensatory signaling activation to maintain mTOR phosphorylation. This means that although the total mTOR pool is reduced, the proportion of remaining mTOR molecules “overactivated” by this compensatory signal may have increased, maintaining the level of p-mTOR. The most critical conclusion should be based on the phosphorylation state of the downstream effector molecule (S6K, 4E-BP1).

.In vivo experiments, it was found that GA had a slow onset of action, and the combined use of GA with DDP took a longer time to show a combined effect. A longer period of use of GA could promote the apoptotic effect of DDP and significantly prolong the survival time of mice. GA is widely found in plants such as Cornus officinalis, Toxicodendron vernicifluum, Quercus cortex, and tea, with mature extraction processes and low production costs. Moreover, it exhibits extremely low toxicity in vivo (48, 49). Therefore, GA can be used clinically as an adjuvant treatment after surgery or as an adjuvant dietary therapy. Long-term postoperative use of GA may help extend the recurrence-free and survival times of patients.

In summary, the active monomer from medicinal plants, gallic acid, exhibits significant anti-ovarian cancer activity with multi-target and multi-pathway characteristics. It can enhance the efficacy of platinum-based drugs, and the combination with platinum-based drugs is a promising anticancer regimen. GA is abundant in dietary sources and has an established safety profile (mouse LD₅₀ 4.3 g/kg). At 50 mg/kg—only 1/86 of the LD₅₀—GA achieved robust efficacy without weight loss or organ toxicity. In patients, equivalent plasma levels (~5 µM free GA) are attainable with 1 – 1.5 g oral supplementation, suggesting feasibility for adjuvant maintenance therapy after cytoreductive surgery. Although the specific mechanisms of action require further research, gallic acid, as a natural plant active monomer, holds promise as a new adjuvant drug for ovarian cancer treatment. However, there are still many shortcomings in this study, such as the ID8 allograft tumor model can better simulate the process of platinum-resistant recurrence, there is still a lack of validation of human xenograft tumors (PDX) and organoid models. Although intraperitoneal administration of mice mimics intraperitoneal chemotherapy, the oral bioavailability of GA, the maximum blood concentration in humans, and the potential drug-drug interaction (DDI) with cisplatin still need to be confirmed by clinical trials. The upstream regulatory mechanism of GA on the CXCL12/CXCR4 axis and the downstream effects of the PI3K/AKT/mTOR pathway have not yet.

This study systematically evaluated the antitumor effects of gallic acid (GA) on ovarian cancer cells and its potential synergistic therapeutic effects with cisplatin (DDP) through in vitro and in vivo experiments. The results demonstrated that GA significantly inhibits the proliferation of ovarian cancer cells and enhances the anticancer effects of DDP by modulating the PI3K/AKT/mTOR signaling pathway. In in vivo experiments, the combination of GA and DDP significantly inhibited tumor growth and prolonged survival in a mouse model of ovarian cancer without apparent toxicity to vital organs. This study provides scientific evidence for the potential use of GA as an adjuvant drug in ovarian cancer treatment, warranting further exploration of its clinical application potential. Although previous studies have reported that GA alone can inhibit the proliferation of ovarian cancer cells, the mechanism of CXCL12/CXCR4-PI3K/AKT/mTOR axis mediated cisplatin sensitivity and survival benefit have not been reported in public. This study reveals the potential of GA in reversing cisplatin resistance for the first time. CXCL12/CXCR4-PI3K/AKT/mTOR signaling pathway significantly enhanced the efficacy of platinum-based chemotherapy. Through the systematic integration of transcriptome, molecular docking and mouse survival model, this study significantly expands the theoretical basis and translational prospects of GA in the treatment of ovarian cancer, provides a promising clinical supplement for patients who fail to receive platinum therapy, and provides a reasonable basis for biomarks-driven clinical trials of GA combined with standard platinum chemotherapy.

Ovarian cancer A2780 and ES - 2 cells were purchased from the National Biomedical Experimental Cell Resource Bank. ID8 cells were donated by the Department of Obstetrics and Gynecology, Peking University People’s Hospital. Normal ovarian IOSE80 cells provided by Medical Experimental Center, Institute of Life Science, Guangxi Medical University. RPMI1640 medium, McCoy ‘5A medium, DMEM high glucose medium, fetal bovine serum, and 0.25% trypsin containing EDTA were purchased from Corning, USA. Other reagents and consumables related to this experiment were mainly purchased from Thermo Fisher Scientific (USA), Beyotime Institute of Biotechnology (China), and Solarbio Science & Technology Co., Ltd. (China). Gallic acid was synthesized and purified and generously provided by Professor Zhijun Song. The instruments used were provided by the Laboratory of the Affiliated Tumor Hospital of Guangxi Medical University.

A2780 cells were cultured in RPMI1640 medium (10 - 040-CVRC, Corning, USA), ES - 2 cells in McCoy’s 5A medium (12330031, Corning, USA), and ID8 and IOSE80 cells in high-glucose DMEM medium (10 - 013-CVRC, Corning, USA). Complete medium was prepared by adding 10% fetal bovine serum (35 - 081-CV, Corning, USA), 1% penicillin-streptomycin solution (C0224, Beyotime Institute of Biotechnology, China), and 1% L-glutamine (ST025, Beyotime Institute of Biotechnology, China). Cells were maintained in a humidified incubator at 37°C with 5% CO2, with medium changes every 2 – 3 days. When the cell density reached approximately 90%, cells were digested with 0.25% trypsin containing EDTA (25 - 053-CI, Corning, USA) and passaged at a 1:3 ratio. Exponentially growing cells in good condition were used for experiments.

Accurately weigh 4.63 mg of gallic acid standard (batch number: 11831 - 201906, China Institute of Food and Drug Control, the content is calculated as 91.5%), put it in a 10 ml volumetric flask, add chromatography methanol to dissolve, dilute to the scale, shake well, and obtain a control solution with a concentration of 0.426 mg/ml. Accurately measure 0.2, 0.6, 1.0, 1.8 and 2.2 ml of the above control solutions in a 10ml volumeic flask, add chromatographic methanol to dilute to the scale, and shake well, that is, the gallic acid series control solution with concentrations of 8.48, 25.44, 42.40, 76.72 and 93.28 μg/ml respectively is obtained. 1 μl of each standard solution was precisely measured, injected into a liquid chromatograph (Shimadzu LD - 40D ultra-high performance liquid chromatograph, Shim-pack GIST HSS-C18 (2.1×100 mm, 2μm) column), and the chromatographic conditions were 0.05% phosphoric acid solution-methanol (93:7) as the mobile phase, and elution at the same degree for 12 minutes; Injection volume: 1μl; Column temperature: 35 °C; Wavelength: 271 nm, record chromatogram. The standard curve of gallic acid was calculated by peak area according to the external standard method. Take gallic acid for the test (provided by Guangxi Medicinal Botanical Garden) 0.26 mg, weigh it precisely, put it in a 10 ml measuring flask, add chromatographic methanol to dissolve and dilute to the scale, shake well, filter with a 0.22μm needle filter, and take the filtrate as the test solution. 1 μl of each of the test solution was precisely measured, injected into a liquid chromatograph, and performed three times in parallel, recording the chromatographic area, substituting the regression curve equation, and calculating the purity of the sample to be 98.34%.

Logarithmically growing A2780, ES - 2, and IOSE80 cells were adjusted to a density of 5×10^4 cells/mL and seeded at 100 µL per well in 96-well plates. After 24 hours, the medium was removed, and GA powder (provided by Guangxi Botanical Garden, purity: HPLC>98.34%) was dissolved in DMSO (D8371, Beijing Solarbio Science & Technology Co., Ltd., China) to prepare a 250 mM GA stock solution. This solution was then diluted with the corresponding complete medium to different concentrations. The 96-well plate was filled with the diluted solutions, and the control group received 100 µL of complete medium per well, with five replicates per group. After 48 hours of incubation, the medium was removed, and 100 µL of complete medium containing 10% CCK - 8 solution (CK04, DOJNDO, Japan) was added to each well. The plate was incubated in the incubator for another 2 hours, and the absorbance at 450 nm was measured using a microplate reader (Synergy H1, BioTek, USA). The cell inhibition rate was calculated as follows: (ODcontrol​−ODblank​)(ODcontrol​−ODtreated​)​×100%. The IC₅₀ values were determined, and the experiment was repeated three times.

For ID8 cells, the density was adjusted to 5×10^4 cells/mL, and 100 µL was seeded per well in 96-well plates. After 24 hours, the medium was discarded and replaced with 100 µL of complete medium containing different concentrations of GA and cisplatin. The experimental groups were set with four concentrations of GA (100 µM, 150 µM, 200 µM, and 250 µM) and four concentrations of cisplatin (5 µM, 10 µM, 20 µM, and 40 µM) for combination. Negative control and blank groups (both containing 1‰ volume fraction of DMSO) were also established, with three replicates per group. After 48 hours of incubation, the medium was discarded, and 100 µL of complete medium containing 10% CCK - 8 reagent was added to each well. The plate was incubated in the incubator for 2 hours, and the OD values at 450 nm were measured. The cell inhibition rates were calculated, and the combination index (CI) (50)was analyzed using CompuSyn software.

Logarithmically growing A2780 and ES - 2 cells were digested and counted, and the density was adjusted to 1×10^5 cells per well and seeded onto cover slips (placed in 6-well plates). After 24 hours of incubation, the medium was replaced with complete medium containing different concentrations (0, 20, 40, and 60 µM) of GA and continued to be cultured for 48 hours. The cover slips were then removed, fixed in 95% ethanol for 20 minutes, stained with hematoxylin (C005S, Beyotime Institute of Biotechnology, China) for 8 minutes, followed by eosin staining for 1 minute, and mounted with glycerin gelatin mounting medium (C0187, Beyotime Institute of Biotechnology, China). The morphological changes of the cells were observed under a microscope (Nikon, Japan) and photographed. This was similar to the IC50 of Bo et al. (51) in lung cancer Calu-cell GA in the range of 10 to 50 μM, and consistent with the significant morphological changes produced by He et al. (10) in ovarian cancer at 40 μM.

The targets of GA were predicted using PubChem, Swiss Target Prediction, and SEA databases, and ovarian cancer-related targets were retrieved from the GeneCards database using “ovarian cancer” as the keyword (all searches were conducted on January 29, 2024). The intersection of GA targets and ovarian cancer-related targets was obtained and imported into the STRING database to construct a protein-protein interaction (PPI) network. The PPI network was then imported into Cytoscape 3.9.1 software, and core targets were identified using the MCC algorithm (52) of the Cyto Hubba plugin. The 3D structure of GA was downloaded from the PubChem database as the ligand, and the corresponding target protein structures were downloaded from the PDB protein database as the receptors. Molecular docking was performed using AutoDockVina 1.1.2 software, Schrodinger Maestro 13.5 software, and the CB-dock2 online molecular docking tool (https://cadd.labshare.cn/cb-dock2/index.php). The ligands and receptors were processed for dehydration and hydrogen addition before docking. The results were visualized using PyMOL software.

Total RNA was extracted from logarithmically growing ID8 cells (1×10^6 per dish) after 24 hours of incubation. The cells were then treated with different concentrations (0, 120, and 150 µM) of GA for 48 hours. Three samples were set for each concentration, and total RNA was extracted using Trizol reagent (15596026, Invitrogen, USA) according to the manufacturer’s instructions. Sequencing was performed by Beijing Novogene Bioinformatics Technology Co., Ltd.

The data were first analyzed for trends, followed by differential gene expression analysis using the DESeq2 algorithm. DEGs were identified based on the criteria of |log2(Fold Change)|≥1 and Padj ≤ 0.05. The DEGs were then subjected to Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analysis.

Logarithmically growing A2780 and ES - 2 cells (1×10^5 per well) were seeded onto cover slips (placed in 6-well plates) and incubated for 24 hours. The medium was then replaced with complete medium containing different concentrations (0, 20, 40, and 60 µM) of GA and continued to be cultured for 48 hours. The cover slips were removed, fixed in 0.5 mL of fixative for 10 minutes, stained with 0.5 mL of Hoechst 33258 staining solution for 5 minutes, and mounted with antifade mounting medium on a slide. Apoptosis was observed under a fluorescence microscope (Nikon, Japan) and photographed.

The density of A2780, ES - 2, and ID8 cells was adjusted to 1.5×10^5 cells/mL and seeded in 6-well plates. After 24 hours, the medium was removed, and A2780 and ES - 2 cells were replaced with complete medium containing different concentrations (0, 20, 40, and 60 µM) of GA. ID8 cells were replaced with complete medium containing different concentrations (0, GA75, GA150, DDP5, GA75+DDP5, GA150+DDP5 µM) of GA. After 48 hours of incubation, the cells were washed with 4°C pre-cooled PBS (P010, Beijing Solarbio Science & Technology Co., Ltd., China), collected by centrifugation, and stained with Annexin V-FITC and PI according to the manufacturer’s instructions (556547, BD Biosciences, USA). The cells were analyzed using a CytoFlex flow cytometer (Beckman Coulter, USA) to detect apoptosis rates.

A2780 and ES - 2 cells treated with different concentrations of GA (0, 20, 40, 60 µM) and ID8 cells treated with different concentrations of GA (0, GA75, GA150, DDP5, GA75+DDP5, GA150+DDP5 µM) were lysed on ice with protein lysis buffer for 20 minutes. The lysates were centrifuged at 4°C, 12,000 rpm for 15 minutes, and the supernatants were collected to extract total protein. Protein concentration was determined using the BCA protein assay method. The protein samples were mixed with 5× protein loading buffer (P0015, Beyotime Institute of Biotechnology, China) and denatured at 99°C for 8 minutes. After electrophoresis and transfer to a membrane, the membrane was blocked and incubated with corresponding primary and secondary antibodies. The bands were visualized, and the relative expression levels were analyzed using ImageJ software.

The vital organs (heart, liver, spleen, lungs, kidneys, and brain) of the mice were fixed in 10% formalin, routinely dehydrated, embedded in paraffin, sectioned, and stained with HE. The pathological changes in the transplanted tumor tissues were observed under an optical microscope.

Paraffin sections were dewaxed with xylene, hydrated in ethanol, and repaired with pH 9.0 EDTA repair solution using high-pressure antigen retrieval. Non-specific staining was blocked with 3% hydrogen peroxide, and the sections were blocked with blocking solution. The sections were incubated with primary antibodies at room temperature for 1.5 hours, followed by secondary antibody incubation for 40 minutes, and stained with DAB. The sections were counterstained with hematoxylin, dehydrated, cleared, and mounted with glycerin gelatin mounting medium. The sections were dried at room temperature and observed under a microscope. The images were analyzed using ImageJ software. Tumor cells with brown-yellow nuclei were considered positive.

Data analysis was performed using SPSS 20.0 statistical software. Quantitative data are presented as mean ± standard deviation (x ± s). Normality tests were conducted for all data, and homogeneity of variance tests were performed before comparing means among multiple groups. One-way analysis of variance was used for group comparisons, and LSD-t tests were used for pairwise comparisons between groups. P<0.05 was considered statistically significant.